{"id":1582,"date":"2026-01-25T15:18:48","date_gmt":"2026-01-25T21:18:48","guid":{"rendered":"https:\/\/zogen.local\/?p=1582"},"modified":"2026-01-25T15:18:48","modified_gmt":"2026-01-25T21:18:48","slug":"immunotherapy-as-an-alternative-to-traditional-cancer-treatment","status":"publish","type":"post","link":"https:\/\/zogen.mx\/en\/inmunoterapia-como-alternativa-al-tratamiento-tradicional-del-cancer\/","title":{"rendered":"Immunotherapy as an alternative to traditional cancer treatment"},"content":{"rendered":"

In recent years, the search for less invasive and more personalized treatments has led to revolutionary advances in the field of oncology. One of the most promising is the Immunotherapy as an alternative to traditional cancer treatment<\/strong>, especially in patients with certain genetic alterations. A recent study from Memorial Sloan Kettering Cancer Center has shown that, in some types of cancer with a specific mutation, it is possible to avoid surgery, chemotherapy, and even radiotherapy thanks to the use of targeted immunotherapy.<\/p>\n\n\n\n

This discovery not only represents a shift in the therapeutic paradigm but also offers new opportunities to improve patients' quality of life. In this article, we explain how this treatment works, which patients could benefit, and why genetic testing is key to accessing this type of therapy.<\/p>\n\n\n\n

What is immunotherapy and how does it work against cancer?<\/h2>\n\n\n\n

Immunotherapy is a form of treatment that stimulates the patient's immune system to recognize and destroy cancer cells. Unlike chemotherapy or radiation, which attack both cancerous and healthy cells, immunotherapy acts more selectively.<\/p>\n\n\n\n

One of the drugs that has recently attracted attention is dostarlibab<\/strong>, An immune checkpoint inhibitor. This drug prevents tumor cells from "tricking" the immune system and hiding from immune attack.<\/p>\n\n\n\n

A game-changing clinical trial<\/h2>\n\n\n\n

Memorial Sloan Kettering Cancer Center led a clinical trial with 103 patients with various types of cancer: rectal, gastric, endometrial, and prostate. All participants shared a genetic characteristic: the mutation MMRd<\/strong> (deficiency in the DNA mismatch repair system). This type of mutation prevents cells from properly repairing their genetic material, creating an ideal environment for cancer growth, but also making it vulnerable to immunotherapy.<\/p>\n\n\n\n

The results were surprising: 100% of patients with rectal cancer<\/strong> They experienced complete tumor remission after receiving dostarlimab for six months. And most impressively, none of them required surgery, chemotherapy, or radiation therapy. Other patients with different types of cancer and the same mutation showed similar responses, with long-term disease control.<\/p>\n\n\n\n

This study clearly demonstrates that Immunotherapy as an alternative to traditional cancer treatment<\/strong>It can be viable, safe, and highly effective, provided the appropriate mutations are identified through specialized genetic testing.<\/p>\n\n\n\n

The fundamental role of genomic testing<\/h2>\n\n\n\n

To access treatments like dostarlimab, a genetic profile of the tumor is essential. Genomic tests can identify mutations such as MMRd or MSI-H (high microsatellite instability), which are predictive markers of a positive response to immunotherapy.<\/p>\n\n\n\n

At Zogen, we facilitate access to advanced genetic testing that analyzes these and other relevant mutations in various types of cancer. We collaborate with specialized international laboratories and support patients throughout the entire process, from sample collection to results interpretation. This allows each patient to receive a personalized treatment strategy based on the biology of their tumor.<\/p>\n\n\n\n

Who can benefit from this approach?<\/h2>\n\n\n\n